SNN Q2 2025 Earnings Call Summary

Smith & Nephew (SNN) Q2 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $1.6 billion for Q2, reflecting a 6.7% underlying growth and 7.8% reported growth, aided by a 110 basis point foreign exchange tailwind.
First Half Revenue: $3 billion, up 5% underlying and 4.7% reported.
Trading Margin: Expanded by 100 basis points to 17.7% in H1, with expectations for full-year margins to be between 19% and 20%.
Earnings Per Share: Increased 37% to $0.335; adjusted EPS rose 14% to $0.429.
Free Cash Flow: Nearly $250 million in H1, with expectations to exceed $600 million for the full year.
Share Buyback: Announced a $500 million buyback for H2 2025, fully funded by cash flow.

2. Strategic Updates and Business Highlights

Growth Drivers: Strong performance in Sports Medicine, Wound Management, and Orthopaedics, with notable advancements in Joint Repair and Robotics.
Operational Improvements: Enhanced inventory management led to a 46-day reduction in Days Sales of Inventory (DSI) to 506 days.
Product Launches: Continued innovation with new products like the CATALYSTEM Hip System and CORIOGRAPH preoperative planning for shoulder replacements.
12-Point Plan: Progress on operational efficiencies, with cumulative savings of $210 million achieved, targeting $120 million to $130 million in 2025.

3. Forward Guidance and Outlook

Revenue Growth: Maintaining full-year growth guidance of 5%, with expectations for a stronger Q3 due to annualizing impacts from China and improved trading days.
Margin Expectations: Anticipate further margin expansion in H2, driven by operational savings and easing headwinds from value-based procurement (VBP) in China.
Long-term Growth: Commitment to innovation and product development, with a focus on sustaining growth beyond 2025.

4. Bad News, Challenges, or Points of Concern

Tariff Impact: Anticipated headwind of $15 million to $20 million in 2025 due to U.S. tariffs, primarily affecting the second half.
Emerging Market Performance: Emerging markets saw a slight decline of 0.2%, with specific challenges in China due to volume-based procurement impacts.
U.S. Knee Performance: Softer growth in U.S. knees attributed to a slowdown in procedures among active surgeons and a strategic focus on higher volume accounts, which may temporarily affect sales.

5. Notable Q&A Insights

Revenue Guidance: Management remains cautious about changing revenue guidance despite stronger Q2 performance, citing macroeconomic uncertainties and a challenging Q4 comparison.
U.S. Knee Strategy: The company is rationalizing its knee portfolio and refocusing on high-volume accounts to improve margins, despite recent softness.
Skin Substitutes: Expected to face headwinds from proposed Medicare reimbursement changes, but management believes they can navigate these challenges effectively.
Engagement with Activist Investors: Ongoing constructive discussions with Sapient, focusing on enhancing shareholder value through operational improvements and strategic growth.

Overall, Smith & Nephew reported solid growth and operational improvements in Q2 2025, while navigating challenges related to tariffs and market dynamics. The company remains committed to its strategic initiatives and innovation pipeline to sustain growth in the coming years.

SNN — Smith & Nephew plc